Please assess the completion status of the following clinical trial:

Trial Title: To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Aged ≥12 years and older inclusive of either sex.~2. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit \[Visit 1\]) with exacerbations (clinical evidence of active symptoms) during the study season for the mountain cedar pollen~3. A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for the AM assessment at the Screening Visit (Visit 1).~Key Exclusion Criteria:~1. Pregnant or lactating women.~2. Plans to travel outside the known pollen area for the investigative site for \> 24 hours during the last 7 days of run in period.~3. History of nasal polyps of other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (such as nasal piercing) or surgery, atopic dermatitis or rhinitis medicamentosa.~4. History of anaphylaxis and/or other severe local reaction(s) to skin testing.~5. History of positive test for HIV, Hepatitis B or Hepatitis C infection.~6. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.~7. Subjects with an active pulmonary disorder or infection.~8. Subjects with posterior subcapsular cataracts or glaucoma.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSP 301 Placebo NS (Type: PLACEBO_COMPARATOR): None
- GSP 301-1 NS (QD) (Type: EXPERIMENTAL): None
- GSP 301-2 NS (BID) (Type: EXPERIMENTAL): None
- Olopatadine HCl-1 NS (QD) (Type: ACTIVE_COMPARATOR): None
- Olopatadine HCl-2 NS (BID) (Type: ACTIVE_COMPARATOR): None
- Mometasone Furoate-1 NS (QD) (Type: ACTIVE_COMPARATOR): None
- Mometasone Furoate-2 NS (BID) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).